With an expedited FDA pathway and rising interest in cannabinoids, the drug development landscape was rapidly advancing in 2025. New CB1 and CB2-targeting candidates were progressing toward regulatory approval for conditions like weight management, pain, and neurological disorders. Both phytocannabinoid and synthetic drugs aimed to follow in the footsteps of Epidiolex, Marinol, Syndros, and Cesamet.
In its 8th year, the Cannabinoid & Endocannabinoid Drug Development Summit featured a new business and investor panel, IP protection sessions, and interactive regulatory discussions, plus insights from the year’s key milestones and clinical lessons shared by leading biotech innovators.
Highlights Included:
Strategic Investment & Business Development Insights:
Join a dedicated panel of investors and industry executives to discover what makes cannabinoid programs attractive for funding. Learn how to structure partnerships and position your pipeline for long-term commercial success.
Advanced Formulation Strategies:
Delve into cutting-edge formulation techniques, including innovative delivery systems and optimized formulations designed to improve bioavailability, enhance stability, and support patient adherence in clinical settings.
Expert Guidance on IP Protection:
Join leading cannabinoid IP lawyers Chris Hayes and Graham Penchik for expert guidance on developing a robust patent strategy. Learn how to safeguard your innovations from early discovery through to commercialization
Regulatory Pathway Navigation:
Hear directly from regulatory experts as they unpack the complexities of global approval pathways for cannabinoid-based therapeutics. Gain actionable insights to overcome regulatory hurdles and accelerate approvals.
Clinical Development Lessons & Milestones:
Access exclusive case studies from pioneering biotechs sharing critical learnings from recent clinical trials. Take away practical strategies to address trial design challenges, placebo control, and achieving regulatory acceptance.
Who You Met?
This summit connected C-level suite, vice presidents, directors and senior scientists who specialised in pre-clinical and clinical development, pharmacology, translational science and regulatory affairs.
What Your Peers Had to Say
